Q3 FY23 Earnings Presentation

• • . Neuroscience 7% growth with strength in U.S. Core Spine, SCS, NV, and ENT Cranial & Spinal Technologies (CST) CST: MSD growth driven by Aible™ ecosystem of spine products LDD growth in U.S. core spine with continued success of CatalyftTM and ModuleX™: partially offset by HSD decline in biologics due to product availability and difficult U.S. comps Strong growth in StealthStation™ navigation & O-arm™ imaging (LDD), Midas Rex™ power tools (HDD), and Mazor TM robotics (high-20's), driven by OUS performance Specialty Therapies (ST) NV: LDD growth in hemorrhagic and ischemic; driven by mid-teens growth in flow diversion, LDD growth in aspiration, and HSD growth in mechanical thrombectomy ENT: Low-20s organic growth driven by strength in NIM Vital TM nerve monitoring systems and recovery in product availability; integration progress of Intersect ENT PH: LDD OUS growth and MSD U.S. growth from continued market expansion, partially offset by continued U.S. competitive pressures Neuromodulation (NM) Aible TM Spinal Surgical Suite Pipeline TM Shield Embolization Device with Shield Technology TM 31% ... ST | $699M +10.4% Y/Y Rep +11.4% Y/Y Org $2,248M +4.9% Y/Y Rep +7.3% Y/Y Org 19% NM | $420M +2.7% Y/Y Rep +6.1% Y/Y Org ....50% CST | $1,128M +2.4% Y/Y Rep +5.3% Y/Y Org Operating Unit Growth Cranial & Spinal Technologies MSD Neurovascular HSD Brain Modulation: LSD decline due to continued replacement headwinds; MSD U.S. new implant growth DTMTM SCS on the Intellis TM platform ENT Low-20s Pelvic Health Neuromodulation MSD MSD SCS: Robust LDD growth driven by new implant share and increased commercial footprint for DPN on Intellis TM; market procedures improving • LDD TDD growth and LSD Interventional growth driven by continued improvements in product availability 12 Q3 FY23 Earnings Presentation | February 21, 2023 Medtronic

View entire presentation